{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:03:43Z","timestamp":1789196623903,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jocd.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T04:21:22Z","timestamp":1547785282000},"page":"212-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Bone Health in Patients With Liver Diseases"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-7705","authenticated-orcid":false,"given":"Christopher J.","family":"Danford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirsh D.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Bonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2019.01.004_bib0001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bmj.1.6105.75","article-title":"Parenteral 1,25-dihydroxycholecalciferol in hepatic osteomalacia","author":"Long","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.jocd.2019.01.004_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.2.6185.309","article-title":"Treatment of osteomalacia associated with primary biliary cirrhosis with oral I-alpha-hydroxy vitamin D3","author":"Compston","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.jocd.2019.01.004_bib0003","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0016-5085(03)01062-X","article-title":"AGA technical review on osteoporosis in hepatic disorders","volume":"125","author":"Leslie","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0004","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0016-5085(95)90033-0","article-title":"Bone disease in cholestatic liver disease","volume":"108","author":"Hay","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0005","first-page":"437","article-title":"Bone health and osteoporosis: a report of the Surgeon General","year":"2004","journal-title":"US Heal Hum Serv"},{"key":"10.1016\/j.jocd.2019.01.004_bib0006","first-page":"1356","article-title":"Factors influencing the development of metabolic bone disease in primary biliary cirrhosis","volume":"85","author":"Gua\u00f1abens","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0007","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0008","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.arth.2004.05.004","article-title":"Operative risk of total hip and knee arthroplasty in cirrhotic patients","volume":"20","author":"Cohen","year":"2005","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.jocd.2019.01.004_bib0009","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3748\/wjg.v24.i31.3513","article-title":"Osteoporosis in primary biliary cholangitis","volume":"24","author":"Danford","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0010","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","author":"Menon","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0168-8278(94)80132-0","article-title":"Cyclosporin a increases the biochemical markers of bone remodeling in primary biliary cirrhosis","volume":"21","author":"Guanabens","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0012","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/gut.49.2.282","article-title":"Osteoporosis in primary biliary cirrhosis revisited","volume":"49","author":"Newton","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jocd.2019.01.004_bib0013","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Gua\u00f1abens","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0014","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/lt.20874","article-title":"Bone mineral density before and after OLT: long-term follow-up and predictive factors","volume":"12","author":"Guichelaar","year":"2006","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jocd.2019.01.004_bib0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/jhep.2001.22758","article-title":"Collagen type I alpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis","volume":"33","author":"Par\u00e9s","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0016","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/jgh.13746","article-title":"Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis","volume":"32","author":"Seki","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0017","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2010.10.014","article-title":"Bone disease in patients with primary sclerosing cholangitis","volume":"140","author":"Angulo","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0018","first-page":"1809","article-title":"Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload","volume":"24","author":"Sinigaglia","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0019","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00198-008-0701-4","article-title":"Association between iron overload and osteoporosis in patients with hereditary hemochromatosis","volume":"20","author":"Valenti","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00198-005-1934-0","article-title":"Bone mineral density in men with genetic hemochromatosis and HFE gene mutation","volume":"16","author":"Guggenbuhl","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0021","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-110-6-430","article-title":"Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or others factors?","volume":"110","author":"Diamond","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0022","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10545-015-9815-y","article-title":"Bone demineralisation in a large cohort of Wilson disease patients","volume":"38","author":"Weiss","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jocd.2019.01.004_bib0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00198-017-4295-6","article-title":"Osteoporosis and bone mineral density in patients with Wilson's disease: a systematic review and meta-analysis","volume":"29","author":"Chenbhanich","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1465-9921-11-173","article-title":"Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency","volume":"11","author":"Duckers","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0025","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.rmed.2014.05.001","article-title":"Prognosis of patients with alpha1-antitrypsine deficiency on long-term oxygen therapy","volume":"108","author":"Ringbaek","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0026","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3748\/wjg.v11.i12.1843","article-title":"Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection","volume":"11","author":"Schiefke","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0027","doi-asserted-by":"crossref","first-page":"e2086","DOI":"10.1097\/MD.0000000000002086","article-title":"Relation between hepatitis C virus exposure and risk of osteoporosis: a nationwide population-based study","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jocd.2019.01.004_bib0028","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Mulligan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jocd.2019.01.004_bib0029","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2014.04.001","article-title":"Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection","volume":"61","author":"Byrne","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4103\/sjg.SJG_452_16","article-title":"Hepatitis C virus infection and risk of osteoporosis: a meta-analysis","volume":"23","author":"Wijarnpreecha","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0031","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0168-8278(00)80314-1","article-title":"Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C","volume":"33","author":"Sol\u00eds-Herruzo","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0032","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2893.2008.01038.x","article-title":"Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy","volume":"15","author":"Hofmann","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jocd.2019.01.004_bib0033","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.trstmh.2010.01.012","article-title":"The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt","volume":"104","author":"Raslan","year":"2010","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jocd.2019.01.004_bib0034","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00223-012-9653-y","article-title":"Association between chronic hepatitis C virus infection and bone mineral density","volume":"91","author":"Lin","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2014.03.007","article-title":"Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study","volume":"61","author":"Hansen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0036","doi-asserted-by":"crossref","first-page":"286","DOI":"10.7326\/0003-4819-117-4-286","article-title":"Long-term bone loss in men: effects of genetic and environmental factors","volume":"117","author":"Slemenda","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0037","first-page":"619","article-title":"Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics","volume":"27","author":"Peris","year":"1992","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0038","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00298430","article-title":"Vertebral fractures and osteopenia in chronic alcoholic patients","volume":"57","author":"Peris","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0039","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12020-012-9639-6","article-title":"Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women","volume":"42","author":"Moon","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.jocd.2019.01.004_bib0040","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00508-012-0211-4","article-title":"The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease","volume":"124","author":"Purnak","year":"2012","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jocd.2019.01.004_bib0041","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2036.2012.05196.x","article-title":"Review article: non-alcoholic fatty liver disease and osteoporosis\u2013clinical and molecular crosstalk","volume":"36","author":"Yilmaz","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jocd.2019.01.004_bib0042","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2036.2011.04924.x","article-title":"Nonalcoholic fatty liver disease is associated with low bone mineral density in obese children","volume":"35","author":"Pardee","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jocd.2019.01.004_bib0043","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2011-3010","article-title":"Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese","volume":"97","author":"Li","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.01.004_bib0044","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/gut.29.3.378","article-title":"Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis","volume":"29","author":"Stellon","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.jocd.2019.01.004_bib0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00223-001-2028-4","article-title":"High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation","volume":"69","author":"Ninkovic","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0046","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1053\/jlts.2003.50242","article-title":"Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem","volume":"9","author":"Carey","year":"2003","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jocd.2019.01.004_bib0047","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s001980170051","article-title":"Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study","volume":"12","author":"Floreani","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0048","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1210\/jc.2009-0835","article-title":"Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis","volume":"94","author":"Gonz\u00e1lez-Calvin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.01.004_bib0049","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00223-013-9797-4","article-title":"Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades?","volume":"93","author":"Monegal","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1440-1746.1996.tb00284.x","article-title":"Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis?","volume":"11","author":"Chen","year":"1996","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0051","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.1840140215","article-title":"Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis","volume":"14","author":"Eastell","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0052","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1359\/jbmr.2003.18.12.2190","article-title":"Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease","volume":"18","author":"Guichelaar","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0053","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/00365520310000681a","article-title":"Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease","volume":"38","author":"Bj\u00f8ro","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0054","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0168-8278(88)80467-7","article-title":"Bone disease after orthotopic liver transplantation","volume":"6","author":"Haagsma","year":"1988","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(94)90324-7","article-title":"Bone loss after orthotopic liver transplantation","volume":"97","author":"Meys","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0056","first-page":"0913","article-title":"High incidence of vertebral osteoporotic fracture within the first year after liver transplantation","volume":"35","author":"Butin","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0057","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/jhep.2002.36357","article-title":"Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry","volume":"36","author":"Guichelaar","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0058","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-103-6-855","article-title":"Bone loss and reduced osteoblast function in primary biliary cirrhosis","volume":"103","author":"Hodgson","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0059","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.0106-9543.2002.01566.x","article-title":"Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease","volume":"22","author":"Ackerman","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.jocd.2019.01.004_bib0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.510280315","article-title":"Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis","volume":"28","author":"Gallego-Rojo","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0061","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/joe.0.1760339","article-title":"Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture","volume":"176","author":"Koshihara","year":"2003","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0062","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1172\/JCI117959","article-title":"Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice","volume":"95","author":"Janes","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocd.2019.01.004_bib0063","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2362.2009.02230.x","article-title":"Lithocholic acid downregulates vitamin D effects in human osteoblasts","volume":"40","author":"Ruiz-Gasp\u00e0","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jocd.2019.01.004_bib0064","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1359\/jbmr.080313","article-title":"Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation","volume":"23","author":"Kawelke","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0065","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/jbmr.2845","article-title":"Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis","volume":"31","author":"Gua\u00f1abens","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0066","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.1840040215","article-title":"Intestinal calcium absorption and vitamin D status in chronic cholestatic liver disease","volume":"4","author":"Bengoa","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0067","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0016-5085(82)80292-8","article-title":"Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D","volume":"83","author":"Herlong","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0068","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0016-5085(82)80291-6","article-title":"Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment","volume":"83","author":"Matloff","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0069","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1359\/jbmr.1998.13.3.393","article-title":"IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures","volume":"13","author":"Devlin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0070","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1210\/jc.2004-0077","article-title":"Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis","volume":"89","author":"Gonzalez-Calvin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2019.01.004_bib0071","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1309\/6VJ4DWGYDU0XYJ8Q","article-title":"Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease","volume":"127","author":"Manco","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0072","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0002-9343(89)90297-0","article-title":"Ethanol reduces bone formation and may cause osteoporosis","volume":"86","author":"Diamond","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0073","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12011-013-9605-z","article-title":"Iron overload inhibits osteoblast biological activity through oxidative stress","volume":"152","author":"He","year":"2013","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0074","article-title":"Influence of exercise on bone remodeling-related hormones and cytokines in ovariectomized rats: a model of postmenopausal osteoporosis","author":"Li","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.jocd.2019.01.004_bib0075","article-title":"Exercise for preventing and treating osteoporosis in postmenopausal women","volume":"6","author":"Howe","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jocd.2019.01.004_bib0076","first-page":"221","article-title":"Osteoporosis after solid organ transplantation","volume":"37","author":"Kulak","year":"2012","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0077","doi-asserted-by":"crossref","unstructured":"Canalis E, Delany AM 2002 Mechanisms of glucocorticoid action in bone. 81:73\u201381.","DOI":"10.1111\/j.1749-6632.2002.tb04204.x"},{"key":"10.1016\/j.jocd.2019.01.004_bib0078","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/00365520310000681a","article-title":"Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease","volume":"38","author":"Bj\u00f8ro","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0079","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000328874","article-title":"Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism","volume":"34","author":"Lee C","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B infection: a randomised, double-bling, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0081","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jocd.2019.01.004_bib0082","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-1440-1-7","article-title":"Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation","volume":"1","author":"Kaemmerer","year":"2012","journal-title":"Transplant Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0084","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.gtc.2016.02.009","article-title":"Metabolic bone disease in primary biliary cirrhosis","volume":"45","author":"Glass","year":"2016","journal-title":"Gastroenterol Clin NA"},{"key":"10.1016\/j.jocd.2019.01.004_bib0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s005350050250","article-title":"Calcitriol for bone loss in patients with primary biliary cirrhosis","volume":"34","author":"Shiomi","year":"1999","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0086","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jocd.2019.01.004_bib0087","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0016-5085(97)70098-2","article-title":"Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years","volume":"113","author":"Guanabens","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0088","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/00365520510023279","article-title":"Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year","volume":"40","author":"Musialik","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0089","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","article-title":"Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis","volume":"89","author":"Sanderson","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2019.01.004_bib0090","doi-asserted-by":"crossref","unstructured":"Rudic JS, Giljaca V, Krstic MN, et al. 2011 Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev CD009144.","DOI":"10.1002\/14651858.CD009144"},{"key":"10.1016\/j.jocd.2019.01.004_bib0091","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial","volume":"33","author":"Lindor","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0092","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(97)80048-7","article-title":"Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis","volume":"26","author":"Wolfhagen","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0093","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0094","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Gua\u00f1abens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0095","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","author":"Gua\u00f1abens","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0096","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-8278(02)00100-9","article-title":"Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation","volume":"37","author":"Ninkovic","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0097","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00296-006-0196-2","article-title":"Pamidronate and osteoporosis prevention in liver transplant recipients","volume":"27","author":"Pennisi","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0098","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1432-2277.2008.00763.x","article-title":"Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial","volume":"22","author":"Monegal","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0099","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/0003-4819-144-4-200602210-00005","article-title":"Annals of internal medicine article zoledronic acid prevents bone loss after liver transplantation","volume":"144","author":"Bronwyn","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0100","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF01622195","article-title":"Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss","volume":"4","author":"Hillard","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2019.01.004_bib0102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1478-3231.1999.tb00034.x","article-title":"Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis","volume":"19","author":"Olsson","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.jocd.2019.01.004_bib0103","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1572-0241.2003.07341.x","article-title":"Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis","volume":"98","author":"Menon","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jocd.2019.01.004_bib0104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2796.2004.01342.x","article-title":"An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis","volume":"256","author":"Ormarsdottir","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0105","first-page":"391","article-title":"Global consensus statement on menopausal hormone therapy","volume":"74","author":"De Villiers","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.jocd.2019.01.004_bib0106","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.5650060108","article-title":"Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis","volume":"6","author":"Diamond","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0107","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on newvertebral fractures in postmenopausalwomen with osteoporosis a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2019.01.004_bib0109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.gastro.2007.10.025","article-title":"Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats","volume":"134","author":"Dresner-Pollak","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0110","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?","volume":"21","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jocd.2019.01.004_bib0111","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2019.01.004_bib0112","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/jbmr.5650091014","article-title":"Bone mass improves in alcoholics after 2 years of abstinence","volume":"9","author":"Peris","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2019.01.004_bib0113","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MCG.0b013e318032388d","article-title":"Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy","volume":"42","author":"Selimoglu","year":"2008","journal-title":"J Clin Gastroenterol"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695018302531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094695018302531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:42:42Z","timestamp":1761082962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094695018302531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1094695018302531"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2019.01.004","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Health in Patients With Liver Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The International Society for Clinical Densitometry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}